A phase 1 trial of Allogene's of-the-shelf CAR-T for lymphoma has been placed on hold by the FDA, after a "chromosomal abnormality" was seen in a patient receiving the cell therapy.
In 2018, the former leadership of team from Kite Pharma founded Allogene, on a mission to outdo the CAR-T cancer cell therapies they had just sold to Gilead for $12 billion with an "off-the
Century Therapeutics has emerged from stealth mode to develop a new generation of ‘off the shelf’ cancer cell therapies, with $250 million backing from investors including Bayer.
Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.